AMENDMENTS TO THE CLAIMS:

- 1. (Canceled).
- (Currently amended) The method of <u>Claim-1</u>, <u>Claim 24</u> wherein the device is selected from a group of balloon-expandable stents, self-expandable stents, and grafts.
- 3. (Currently amended) The method of Claim 1, Claim 24 wherein

the component for reducing or preventing the formation of thrombi is selected from a group of heparin, sodium heparin, low molecular weight heparin, hirudin, argatroban, forskolin, vapiprost, prostacyclin and prostacyclin analogs, D-phe-pro-arg-chloromethylketone, dipyridamole, glycoprotein IIb/IIIa platelet membrane receptor antibody, and recombinant hirudin; and

the component for reducing or preventing the infiltration of macrophages in the thrombi is selected from a group of aspirin, diclofenac, etodolac, ibuprofen, ketoprofen, ketorolac, nabumetone, naproxen, oxaprozin, clobetasol, diflucortolone, flucinolone, halcinolonide, halobetasol, dexamethasone, betamethasone, corticol, cortisone, prednisone, and prednisolone.

- 4. (Currently amended) The method of <u>Claim 1</u>, <u>Claim 24</u> wherein the coating includes an ethylene vinyl alcohol copolymer or a poly(n-butyl methacrylate) polymer.
- 5.-7. (Canceled).
- 8. (Withdrawn)
- 9. (Canceled).

Attorney Docket No.: 50623.00026

10. (Currently amended) A stent for inhibiting restenosis of a mammalian blood vessel, comprising a generally tubular structure carrying an active component, wherein the active component comprises:

an anti-thrombogenic substance selected from a group of heparin, sodium heparin, low molecular weight heparin, hirudin, argatroban, forskolin, vapiprost, prostacyclin and prostacyclin analogs, D-phe-pro-arg-chloromethylketone, dipyridamole, glycoprotein IIb/IIIa platelet membrane receptor antibody, and recombinant hirudin; and

an anti-inflammatory substance selected from a group of diclofenac, eto-dolac, ibuprofen, ketoprofen, ketorolac, nabumetone, naproxen, oxaprozin, clobetasol, diflucortolone, flucinolone, halcinolonide, halobetasol, betamethasone, corticol, cortisone, prednisone, and prednisolone.

- 11. (Canceled).
- 12. (Currently amended) The stent of Claim 10, Claim 26 wherein the stent has an the polymeric coating comprises an ethylene vinyl alcohol or a poly(n-butyl methacrylate) coating which contains the active component polymer.
- 13. (Withdrawn)
- 14. (Withdrawn)
- 15. (Canceled).
- 16. (Withdrawn)
- 17. (Withdrawn)

Attorney Docket No.: 50623.00026

- 18. (Previously presented) A stent comprising a coating having a first region and a second region disposed beneath the first region, the first region having a substance for the treatment of thrombus formation and the second region having a steroidal or non-steroidal anti-inflammatory substance.
- 19. (Previously presented) A stent comprising a first layer containing an antiinflammatory drug and a second layer disposed over the first layer, wherein the second layer reduces or prevents the formation or accumulation of thrombi on the stent.
- 20. (Previously presented) The stent of Claim 19, wherein the second layer is made of a material comprising polytetrafluoroethylene.
- 21. (Withdrawn)
- 22. (Withdrawn)
- 23. (Withdrawn)
- 24. (New) A method for inhibiting restenosis of a blood vessel wherein the method comprises the step of

implanting a device into the blood vessel of a patient wherein the device comprises a coating including

a first region having a component for reducing or preventing the formation of thrombi combined with a polymer; and

a second region having a component for reducing or preventing infiltration of macrophages in the thrombi,

wherein the second region of the coating is positioned beneath the first re-

gion.

25. (New) A method for inhibiting restenosis of a blood vessel wherein the method comprises the step of

implanting a device into the blood vessel of a patient wherein the device comprises a coating including

a first region having a component for reducing or preventing the formation of thrombi; and

a second region having a component for reducing or preventing infiltration of macrophages in the thrombi,

wherein the second region of the coating is positioned beneath the first region.

26. (New) The stent of Claim 10 wherein the stent has a polymeric coating which contains the active component.